de Mascarel A
Laboratoire d'Anatomie Pathologique, Université de Bordeaux II, France.
Nouv Rev Fr Hematol (1978). 1994 Apr;36(2):165-6.
As in the other myeloproliferative disorders, it is classical to practice a bone marrow biopsy (MB) in the assessment of Polycythemia Vera (PV). Actually, MB which is a non dangerous and cheap test, will enable to evaluate marrow cellularity, to analyse each myeloid lineage quantitatively and qualitatively in order to determine which one is the most affected and to study reticulin network. In 90% of cases, MB will confirm the clinical and biological diagnosis of PV (megakaryocytic hyperplasia with dysmegakaryopoiesis) and show an increase in reticulin network in more than 25% of cases. However, in 10% of cases, BM will be quite normal. This can be explained by heterogeneity of lesions or a superficial biopsy sampling a few medullar spaces which are often hypocellular. At diagnosis time, myelofibrosis does not seem to be a bad histo-prognosis criterion. In the management of the patient with PV, MB is necessary to detect myelofibrosis and/or AL.
与其他骨髓增殖性疾病一样，在真性红细胞增多症（PV）的评估中进行骨髓活检（MB）是很常见的。实际上，MB是一种无危险且成本低廉的检查，能够评估骨髓细胞密度，对各髓系谱系进行定量和定性分析，以确定受影响最严重的谱系并研究网状纤维网络。在90%的病例中，MB将证实PV的临床和生物学诊断（伴有巨核细胞生成异常的巨核细胞增生），并在超过25%的病例中显示网状纤维网络增加。然而，在10%的病例中，骨髓将基本正常。这可以通过病变的异质性或仅取少数常为细胞减少的髓腔进行浅表活检来解释。在诊断时，骨髓纤维化似乎并非不良的组织学预后标准。在PV患者的管理中，MB对于检测骨髓纤维化和/或急性白血病是必要的。
